Patients' subjective rating of mental health improvement in a randomised controlled trial

Psychiatry Research

Volumn 229, Issue 1-2, 2015, Pages 593-595

  Hayhurst, Karen P ^a   Drake, Richard J ^a   Massie, Jennifer A ^b   Dunn, Graham ^c   Lewis, Shôn W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Antipsychotic; Assessment; Schizophrenia

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; AGED; ANTIPSYCHOTIC NON NEUROLOGICAL SIDE EFFECTS RATING SCALE; ARTICLE; ATTITUDE ASSESSMENT; CALGARY DEPRESSION SCALE; DRUG ATTITUDE INVENTORY; FEMALE; HUMAN; KEMP COMPLIANCE SCALE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT SATISFACTION; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SELF CONCEPT; SIDE EFFECT ASSESSMENT; SIMPSON-ANGUS SCALE; CONTROLLED STUDY; FOLLOW UP; MENTAL HEALTH; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; SINGLE BLIND PROCEDURE; TRENDS;

ANTIPSYCHOTIC AGENTS; DIAGNOSTIC SELF EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL HEALTH; SCHIZOPHRENIA; SINGLE-BLIND METHOD;

EID: 84939467653     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.07.038     Document Type: Article

References (22)

1. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990, 3:247-251.
2. Angermeyer M.C., Löffler W., Müller P., Schulze B., Priebe S. Patients' and relatives' assessment of clozapine treatment. Psychol. Med. 2001, 31:509-517.
3. Awad A.G., Voruganti L.N.P. The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia. CNS Drugs 2013, 27:625-636.
4. Barnes T.R.E. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:672-676.
5. Bartkó G., Váradi H., Simon L., Linka E., Tüske T., Szabó T., Sántha J. Patient satisfaction after switching from conventional to new atypical antipsychotics in schizophrenia. Int. J. Psychiatry Clin. Pract. 2002, 6:9-14.
6. Bentall R., Day J. Psychological factors and neuroleptic therapy: some neglected issues. Int. Rev. Psychiatry 1994, 6:217-225.
7. Bossie C.A., Lasser R.A., Zhu Y., Gharabawi G.M., Kane J.M. Remission in schizophrenia and patient ratings of health outcomes. Schizophr. Bull. 2005, 31:475-476.
8. Buckley P.F., Wirshing D.A., Bhushan P., Pierre J.M., Resnick S.A., Wirshing W.C. Lack of insight in schizophrenia. Impact on treatment adherence. CNS Drugs 2007, 21:129-141.
9. Gray R., Rofail D., Allen J., Newey T. A survey of patient satisfaction with and subjective experiences of treatment with antipsychotic medication. J. Adv. Nurs. 2005, 52:31-37.
10. Guy W. ECDEU Assessment Manual for. Psychopharmacology. US Govt. Printing Office, Washington 1976.
11. Hayward P., Chan N., Kemp R., Youle S., David A. Medication self-management: a preliminary report on an intervention to improve medication compliance. J. Ment. Health 1995, 4:511-517.
12. Heinrichs D.W., Hanlon T.E., Carpenter W.T. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984, 10:388-398.
13. Hellewell J.S. Patients' subjective experiences of antipsychotics. Clinical relevance. CNS Drugs 2002, 16:457-471.
14. Hogan T.P., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol. Med. 1983, 13:177-183.
15. Jones P.B., Barnes T.R.E., Davies L., Dunn G., Lloyd H., Hayhurst K.P., Murray R.M., Markwick A., Lewis S.W. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia. Arch. Gen. Psychiatry 2006, 63:1079-1087.
16. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (panss) for schizophrenia. Schizophr. Bull. 1987, 13:261-276.
17. Kikkert M.J., Schene A.H., Koeter M.W.J., Robson D., Born A., Helm H., Nose M., Goss C., Thornicroft G., Gray R.J. Medication adherence in schizophrenia: exploring patients', carers' and professionals' views. Schizophr. Bull. 2006, 32:786-794.
18. Lewis S.W., Barnes T.R.E., Davies L., Murray R.M., Dunn G., Hayhurst K.P., Markwick A., Lloyd H., Jones P.B. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr. Bull. 2006, 32:715-723.
19. Liraud F., Droulout T., Parrot M., Verdoux H. Agreement between self-rated and clinically assessed symptoms in subjects with psychosis. J. Nerv. Ment. Dis. 2004, 192:352-356.
20. Rabinowitz J., Levine S.Z., Medori R., Oosthuizen P., Koen L., Emsley R. Concordance of patient and clinical ratings of symptom severity and change of psychotic illness. Schizophr. Res. 2008, 100:359-360.
21. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 1970, 45:11-19.
22. Yusufi B.Z., Mukherjee S., Aitchison K., Dunn G., Page E., Barnes T.R. Inter-rater reliability of the antipsychotic non-neurological side effects scale (ANNSERS). Schizophr. Bull. 2005, 31:574.